DrugPatentWatch Database Preview
TAZVERIK Drug Profile
Email this page to a colleague
Which patents cover Tazverik, and when can generic versions of Tazverik launch?
Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-two patents protecting this drug.
This drug has two hundred and eighty-nine patent family members in thirty-eight countries.
The generic ingredient in TAZVERIK is tazemetostat hydrobromide. Additional details are available on the tazemetostat hydrobromide profile page.
DrugPatentWatch® Generic Entry Outlook for Tazverik
Tazverik will be eligible for patent challenges on January 23, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 11, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TAZVERIK
| International Patents: | 289 |
| US Patents: | 22 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 58 |
| Clinical Trials: | 4 |
| Patent Applications: | 278 |
| Drug Prices: | Drug price information for TAZVERIK |
| What excipients (inactive ingredients) are in TAZVERIK? | TAZVERIK excipients list |
| DailyMed Link: | TAZVERIK at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for TAZVERIK
Generic Entry Date for TAZVERIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TAZVERIK
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dana-Farber Cancer Institute | Phase 1 |
| Pfizer | Phase 1 |
| Epizyme, Inc. | Phase 1/Phase 2 |
US Patents and Regulatory Information for TAZVERIK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | |||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Y | Get Started Free | ||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TAZVERIK
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2836491 | Get Started Free |
| South Korea | 20200003422 | Get Started Free |
| Denmark | 2825161 | Get Started Free |
| Hong Kong | 1213264 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
